Moteur de recherche d’entreprises européennes
Financement de l’UE (8 000 000 €) : La biomécanique computationnelle et la bio-ingénierie de l’impression 3D pour développer un dispositif d’assistance ventriculaire biologique régénérative … Hor01/01/2020 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
La biomécanique computationnelle et la bio-ingénierie de l’impression 3D pour développer un dispositif d’assistance ventriculaire biologique régénérative personnalisé afin de fournir un soutien fonctionnel durable aux cœurs endommagés
Ischemic heart disease is the main cause of death in the EU, straining patients and economies. Regenerative Medicine has failed at delivering a definitive solution, and even the breakthrough of cell reprogramming, biomaterials or 3D printing, have not been able to find a curative solution. Generating a muscle with efficient pumping requires a careful recapitulation of the myocardial architecture. BRAV∃ is born with the ambition of shaping this quantum leap in the field. The overall concept is to provide a lasting functional support to injured hearts through the fabrication of regenerative personalized advanced tissue engineering-based biological ventricular assist devices (BioVADs). To do so, we will apply multimodal deep cardiac phenotyping, coupled to advanced Computational Modelling and biomechanical analysis in a large animal model of disease, to create a personalised 3D printable design. We will for the first time create a fibre-reinforced human heart-sized cardiac tissue able to recapitulate the low Young´s Modulus of the myocardium while withstanding pressures generated during the cardiac circle. Using the latest human induced pluripotent stem cell (hiPSC) technology and industrial-scale growth and differentiation, we will cellularize this novel human heart-sized constructs, creating a highly efficiently aligned cardiac tissue (including vasculature). BioVADs will be matured in in-Consortium built electromechanical stimulation bioreactors before transplantation in a porcine model of disease. We anticipate our BioVADs will constitute a one-shot regenerative treatment of IHD, decreasing the burden on healthcare providers and improving the quality of life of patients. Crucially, we will for the first time generate a wealth of information on heart development at a human scale. Delivering this novel application whilst developing the technological environment (bioreactor, chamber, pacemaker) will boost the capacity of the EU to grow economically and lead the field.
| AE Medicalis B.V. | 150 000 € |
| 471 750 € | |
| CIAOTECH Srl | 0,00 € |
| Ebers Medical Technology SL | 559 375 € |
| Fundacio Institut de Bioenginyeria de Catalunya | 740 000 € |
| 770 000 € | |
| Katholieke Universiteit Leuven | 555 250 € |
| 579 375 € | |
| 0,00 € | |
| PNO Innovation SL | 458 750 € |
| 441 875 € | |
| Technische Universiteit Eindhoven | 490 000 € |
| UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT | 683 125 € |
| Universidad de Navarra | 800 500 € |
| Universidad de Zaragoza | 560 000 € |
| Universitair Medisch Centrum Utrecht | 740 000 € |
| Viscofan SA | 0,00 € |
https://cordis.europa.eu/project/id/874827
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "AE Medicalis B.V. - Financement de l’UE (8 000 000 €) : La biomécanique computationnelle et la bio-ingénierie de l’impression 3D pour développer un dispositif d’assistance ventriculaire biologique régénérative personnalisé afin de fournir un soutien fonctionnel durable aux cœurs endommagés"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
